Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
#1PRI RANKED
Most Cited Paper
in HIV Research and Treatment
18 Months Post-Publication
Class of 2026
“Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/hiv-research-and-treatment/2026/
Topics
lenacapavir · emtricitabine-tenofovir alafenamide · F/TAF · emtricitabine-tenofovir disoproxil fumarate · F/TDF · HIV pre-exposure prophylaxis (PrEP) · HIV pre-exposure prophylaxis (PrEP) · subcutaneous administration · Twice-yearly dosing · cisgender women · adolescent girls and young women · HIV incidence · HIV incidence · Adherence · injection site reactions · phase 3 trial · PURPOSE 1
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited HIV Research and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/hiv-research-and-treatment/2026. Accessed 2026-07-21. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459